New England Journal of Medicine Highlights Potential Disease Modification in Dravet Syndrome with Zorevunersen

Published March 5, 2026, in The New England Journal of Medicine, groundbreaking data suggest that zorevunersen, an investigational RNA medicine, may offer the potential to modify the course of Dravet syndrome, a rare and severe genetic neurodevelopmental disorder.^1,3 This marks the first time data have demonstrated such potential for disease modification in individuals with Dravet syndrome.

Understanding Dravet Syndrome

Dravet syndrome is characterized by frequent and prolonged seizures, often beginning in infancy, alongside cognitive and behavioral challenges. It is caused by mutations in the SCN1A gene, leading to a deficiency in the Nav1.1 sodium channel protein.³

Zorevunersen: A Novel Approach

Zorevunersen is designed to restore protein expression by harnessing the body’s RNA machinery. Specifically, it targets the underlying genetic cause of Dravet syndrome by increasing the production of the Nav1.1 protein.³

Key Findings from Clinical Studies

The publication in The New England Journal of Medicine includes results from Phase 1/2a studies and ongoing open-label extension (OLE) studies. These studies demonstrated:

• Substantial and durable reductions in seizure frequency.³
• Improvements in cognitive function and behavior.³
• These positive effects were observed in individuals treated with zorevunersen in addition to standard anti-seizure medications (ASMs).³

Ongoing Research

The promising data from these studies are supporting an ongoing global Phase 3 EMPEROR study, further investigating the efficacy and safety of zorevunersen in a larger patient population.³

Implications for Patients

These findings offer hope for individuals and families affected by Dravet syndrome. While further research is needed, zorevunersen represents a potentially transformative treatment option that addresses the root cause of the disease, rather than just managing its symptoms.³

About The New England Journal of Medicine

The New England Journal of Medicine is a leading peer-reviewed medical journal, publishing original research, review articles, and clinical case studies.² Issues from 2026 are available for review, including Volume 394, Issue 10, published March 5, 2026.²

References

1. Image Challenge | The New England Journal of Medicine
2. Previous Issues | 2026 : The New England Journal of Medicine
3. The New England Journal of Medicine Publishes First Data to Demonstrate the Potential for Disease Modification in Dravet Syndrome